Get access

Adolescents with acute lymphoblastic leukaemia: Emerging from the shadow of paediatric and adult treatment protocols

Authors

  • Ramya Ramanujachar MRCPCH,

    1. Department of Molecular Haematology, Institute of Child Health, London, United Kingdom
    Search for more papers by this author
  • Sue Richards PhD,

    1. Childhood ALL Collaborative Group Secretariat, Clinical Trial Service Unit, Oxford, United Kingdom
    Search for more papers by this author
  • Ian Hann MD,

    1. Department of Molecular Haematology, Institute of Child Health, London, United Kingdom
    2. Department of Haematology, Great Ormond Street Hospital for Children, London, United Kingdom
    Search for more papers by this author
  • David Webb MD

    Corresponding author
    1. Department of Haematology, Great Ormond Street Hospital for Children, London, United Kingdom
    • Department of Haematology, Great Ormond Street Hospital for Children, Great Ormond Street, London WC1N 3EJ, United Kingdom.
    Search for more papers by this author

Abstract

Adolescents and young adults (AYA) with acute lymphoblastic leukaemia (ALL) constitute a distinct population from children and older adults. Based on patterns of referral, they may be treated by either paediatric or adult oncologists. As a group, AYA with ALL have a worse survival and event-free survival (EFS) compared to that achieved by younger children. A systematic review of all published clinical trials, which provide data on treatment and outcome of adolescents with ALL, has been summarised in an effort to determine whether they should be treated on paediatric or adult type protocols. Adolescents appear to have a consistent survival advantage when treated on paediatric regimens. Pediatric Blood Cancer 2006;47:748–756. © 2006 Wiley-Liss, Inc.

Get access to the full text of this article

Ancillary